LC
MRK icon

Lawood & Co’s Merck MRK Stock Holding History

Lawood & Co’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.32M Sell
22,854
-444
-2% -$61.4K 2.3% 13
2026
Q2 		$2.99M Sell
23,298
-145
-0.6% -$17K 2.03% 14
2026
Q1 		$2.82M Sell
23,443
-1,015
-4% -$117K 2.62% 11
2025
Q4 		$2.57M Buy
+24,458
New +$2.3M 2.44% 12

Other funds holding MRK

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
CAM
Cacti Asset Management Atlanta, Georgia $1.89B AUM 58.55% 1-Year Est. Return
DLA
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
RT
Rockland Trust Hanover, Massachusetts $2.61B AUM 14.26% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
QPBE
Quintet Private Bank (Europe) Luxembourg $2.28B AUM 23.89% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.32B AUM 21.6% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
OGC
Oak Grove Capital North Hampton, New Hampshire $2.21B AUM 127.51% 1-Year Est. Return

Lawood & Co's MRK Position: Q3 2026 in Review

Lawood & Co reduced its Merck (MRK) stake by 1.9% in Q3 2026, selling an estimated $61.4K and leaving 22,854 shares worth $3.32M. The position accounts for 2.3% of the portfolio, ranked #13.

Lawood & Co first reported a position in MRK in Q4 2025 and has held it in 4 quarters since. 203 funds tracked by Wall St. Rank hold MRK as of Q3 2026.

  • Lawood & Co held 22,854 shares of Merck worth $3.32M as of Q3 2026.
  • Lawood & Co sold 444 Merck shares in Q3 2026, an estimated $61.4K.
  • Merck made up 2.3% of Lawood & Co's portfolio in Q3 2026, its #13 holding.
  • Lawood & Co first reported a position in Merck in Q4 2025 and has held it in 4 quarters since.
  • 203 funds tracked by Wall St. Rank held Merck as of Q3 2026.

Based on Lawood & Co's 13F filing for Q3 2026, filed 9 Oct 2026.